When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

So, you’re looking to get better at coding with Python, and maybe you’ve heard about LeetCode. It’s a pretty popular place to practice coding problems, especially if you’re aiming for tech jobs.

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Speaker Mike Johnson is not planning to allow Democrats’ newest congresswoman-elect to be sworn-in until her party agrees to end the government shutdown, despite telling CNN earlier Tuesday that he ...

Last night, '90s emo pioneers Knapsack reunited for a show at Soda Bar in San Diego, CA. The one-off show was announced this past June and precedes the band's appearance at Best Friends Festival later ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Figure 1. Neural networks can store and recall information. In a recall task where the desired output pattern is identical to the input pattern, several patterns can ...

Another name for brute force is exhaustive search. In these algorithms you consider every possible solution in the solution domain to find the optimal solution. Depending on the type of problem that ...